Year All 2026 2025 2024 2023 2022 2021 2020 Sep 30, 2026 Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 PDF Version Sep 21, 2026 Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 PDF Version Sep 14, 2026 Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer PDF Version Sep 01, 2026 Q32 Bio to Participate in Upcoming September Investor Conferences PDF Version Aug 05, 2026 Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update PDF Version Jul 14, 2026 Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants PDF Version Jul 13, 2026 Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PDF Version Jul 13, 2026 Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata PDF Version Jul 10, 2026 Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 PDF Version May 27, 2026 Q32 Bio Announces $55 Million Private Placement Financing PDF Version
Sep 30, 2026 Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026 PDF Version
Sep 21, 2026 Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026 PDF Version
Sep 14, 2026 Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer PDF Version
Aug 05, 2026 Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update PDF Version
Jul 14, 2026 Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants PDF Version
Jul 13, 2026 Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PDF Version
Jul 13, 2026 Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata PDF Version
Jul 10, 2026 Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 PDF Version